All In Biotech

Drug Trial Radar · NCT04171739

Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim

A Phase I, Open Label Study in Healthy Subjects to Evaluate the Effect of Itraconazole and Rifampicin Upon the Pharmacokinetics of a Single Oral Dose of Olorofim.

Last checked: Nov 19, 2026Latest source record: Jul 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Nov 18, 2019

Primary completion

Feb 11, 2020

Study completion Feb 11, 2020

Sponsor

Lead sponsor
F2G LtdIndustry
Sponsor type
Industry
Collaborators
Hammersmith Medicines Research
First posted
Nov 21, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, single-centre, fixed-sequence, open label, drug-drug interaction study in 2 groups of healthy subjects. Group A: to evaluate the effects of itraconazole, a strong inhibitor of cytochrome P450 3A (CYP3A), upon the pharmacokinetics of olorofim . Group B: t o evaluate the effects rifampicin, a strong inducer of CYP3A, upon the pharmacokinetics of olorofim .

Conditions

  • Healthy

Interventions

  • Itraconazole oral solutionDrug

    200 mg once daily on Days 6 to 15

  • Rifampicin Oral CapsuleDrug

    600 mg once daily on Days 6 to 15

  • OlorofimDrug

    Single oral dose on Days 1 and 11

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. maximum plasma concentration (Cmax) for olorofim.Time frame: 16 days
  2. Area under the concentration-time curve to time of last quantifiable concentration (AUC0-tlast) for olorofim.Time frame: 16 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hammersmith Medicines Research

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.